Who Paid My Doc
Danyelza
Drug Oncology
NDC 73042-201-01
General payments
$530,155
Research payments
$1,871,957
Through program year 2024, $530,155 in general payments and $1,871,957 in research payments were reported against Danyelza (Oncology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
8 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | General | $208,819 | 159 |
| 2024 | Research | $869,728 | 37 |
| 2023 | General | $75,412 | 126 |
| 2023 | Research | $465,426 | 25 |
| 2022 | General | $214,896 | 147 |
| 2022 | Research | $319,126 | 11 |
| 2021 | General | $31,027 | 57 |
| 2021 | Research | $217,677 | 15 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2024.
The top 5 of 17 specialties; each share is of general payments naming this product to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.
The top 5 of 21 states; each share is of general payments naming this product in 2024 where a state was reported.
Records
489 general · 88 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.